Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant

Recruiting

25-50 years

All

Phase N/A

10 participants needed

1 Location

Brief description of study

This study aims to determine what underlies the antidepressant effects of sleep deprivation. A novel measure of glutamate imaging, GluCEST, will be used to assess changes in glutamatergic activity following total sleep deprivation.

Detailed description of study

Ten individuals (aged 25-50) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation. Both clinician-administered and subjective mood measures will be collected.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: major depressive disorder, depression
Age: Between 25 Years - 50 Years
Gender: All

Inclusion Criteria:

Age between 25 and 50 years
Current depression as assessed on the SCID
Stable, normally-timed sleep-wake cycle as determined by interview, 1 week daily sleep log, and 1-week wrist actigraphic evidence, and defined by (a) Habitual nocturnal sleep duration between 6h and 9h (b) Habitual morning awakening between 0600h and 0800h.
Able to comprehend English, as all questionnaires are in this language
Ability to provide informed consent

Exclusion Criteria:

Shift work, transmeridian travel or irregular sleep/wake routine in past 60 days
A sleep disorder other than insomnia, as determined by history or actigraph
History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders as assessed on the SCID
Previous electroconvulsive therapy in the past 6 months
Alcohol or drug abuse in the past year based upon the SCID or urine toxicology screen
A current smoker
Any significant medical or neurological illness that impacts brain function or impedes participation
History of head trauma with significant loss of consciousness
Metallic implants, pacemakers or tattoos, or other contraindications to MRI
Claustrophobic, or intolerant of the scanner environment
Visual or auditory impairment severe enough to compromise task performance as judged by the PI
For women, pregnancy will exclude participation.

Updated on 01 Aug 2024. Study ID: 853162

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).